Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
Expert Video - How can communities of color increase their participation in clinical trials?
Dr. Robert Winn, director of Virginia Commonwealth University's Massey Cancer Center, discusses the importance of a team approach to removing barriers to clinical trial participation, especially for communities of color. Dr. Winn describes reframing the concept of clinical trials as community-based opportunities for access to care, rather than an "experiment" that exploits people of color.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Section: Targeted Therapy in NSCLC
Expert Videos
Animation - Targeted Therapy in NSCLC
Slide Show - Targeted Therapy in NSCLC
1.
What is targeted therapy for lung cancer?
2.
What targeted therapies are used for people with the EGFR mutation?
3.
What targeted therapies are used for people with the ALK mutation?
4.
What targeted therapies are used for people with the ROS1 mutation?
5.
What is the importance of combination therapies for BRAF?
6.
What is the future of combination therapy for lung cancer?
7.
Can biomarker testing help identify clinical trial opportunities for me?
8.
How can communities of color increase their participation in clinical trials?
